Phase 1 Study of NTB-928 in R/R OC

Conditions

• Relapsed/Refractory Ovarian Carcinoma

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• NTB-928 — DRUG
  NTB-928 is an investigational study drug administered as an intravenous infusion.

Study Details

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?

Key Dates

First listed

Jul 8, 2026

Start date

Jun 29, 2026

Status verified

Jul 2026

Primary completion

Jun 30, 2028

Completion

Feb 28, 2029

Study Design

Enrollment

90 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: NTB-928 Treatment

Primary Outcome Measure

Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928 [ Time Frame: Up to 35 days ]

Central Contacts

• Clinical Trial Information
  510-392-0929
  [email protected]

Locations (2)

Find similar trials in Lake Success, NY